Welcome to our dedicated page for Smith & Nephew Plc SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Smith & Nephew Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Smith & Nephew Plc's regulatory disclosures and financial reporting.
Smith & Nephew plc has applied to the London Stock Exchange for 150,000 ordinary shares of US20¢ each to be admitted to trading. The shares are expected to start trading on 6 July 2026.
The new shares are reserved under a block admission and will be used to settle awards made under the company’s employee share plans. Once issued, they will rank pari passu, meaning they will have the same rights, benefits, and status as the existing ordinary shares already in circulation.
Smith & Nephew plc reports its updated share capital and voting rights position as at 30 June 2026. The company has total issued share capital of 877,733,750 ordinary shares of US20¢ each, which includes 32,697,503 ordinary shares held in treasury.
Because treasury shares do not carry voting rights, the company’s share capital with voting rights consists of 845,036,247 ordinary shares, each carrying one vote. Shareholders are advised to use this figure as the denominator when assessing whether they must notify holdings or changes in holdings under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reports a TR-1 notification of major holdings showing that an investor group linked to Cevian Capital has increased its position in the company.
The total holding now represents 13.206621% of voting rights, equal to 111,788,454 voting rights, up from a previously notified level of 13.056468%. All voting rights are attached directly to shares, with no additional exposure through financial instruments. The holding is split between Cevian Capital II Master Fund L.P. at 12.018425% and Cevian Capital II Co-Investment - Series P L.P. at 1.188196%, both controlled by Cevian Capital II G.P. Limited.
Smith & Nephew plc reports a TR-1 notification of major holdings showing that entities related to Cevian Capital have increased their stake in the company. The notification discloses that a total of 110,517,469 voting rights are now held, representing 13.056468% of Smith & Nephew’s voting rights, up from a previously reported 12.235936%. All voting rights are held through shares rather than financial instruments, indicating a purely equity-based position. The holding is structured primarily through Cevian Capital II Master Fund L.P. and Cevian Capital II Co-Investment - Series P L.P., which together account for the disclosed percentage.
Cevian Capital II GP Limited reports beneficial ownership of 110,804,501 Ordinary Shares of Smith & Nephew plc, representing 13.09% of the company’s outstanding shares. The stake gives Cevian sole voting and dispositive power over these shares.
The shares were acquired for approximately USD $1,533,290,892, funded from the Cevian funds’ general working capital. The ownership percentage is based on 846,457,637 Ordinary Shares outstanding as of June 18, 2026, as disclosed on Smith & Nephew’s website.
Smith & Nephew plc reports a TR-1 notification of major holdings. Aurora Nominees Limited now holds 103,717,469 indirect voting rights in the company, representing 12.235936% of total voting rights, up from 12.074433% previously. The holding is linked to funds controlled by Cevian Capital II G.P. Limited.
Smith & Nephew plc reports a TR-1 notification showing that funds managed by Cevian Capital now control 12.074433% of its voting rights, representing 102,493,881 voting rights attached to shares. This stake is held indirectly, with no additional voting rights through financial instruments.
The holding has increased from a previously notified level of 11.183442%. The position is primarily held via Cevian Capital II Master Fund L.P. with 10.889586% of voting rights and Cevian Capital II Co-Investment - Series P L.P. with 1.184847%, both ultimately controlled by Cevian Capital II G.P. Limited.
Smith & Nephew plc reported routine share purchases by its Chief Executive Officer and senior managers through an employee plan linked to dividend reinvestment. The Company’s Employee Stock Purchase Plan bought American Depositary Shares (ADS) under the Dividend Re-Investment Plan following the 2025 final dividend paid on 27 May 2026.
On 3 June 2026, ADS in Smith & Nephew plc were acquired on the New York Stock Exchange at a price of $29.8328 per ADS. Participants included CEO Deepak Nath, the Chief Quality & Regulatory Affairs Officer, the President of Global Operations, and the President of Sports Medicine.
Cevian Capital II GP Limited has updated its ownership disclosure for Smith & Nephew plc, reporting beneficial ownership of 101,046,788 ordinary shares. This represents 11.88% of the company’s ordinary shares, based on 850,209,708 shares outstanding as of May 31, 2026.
The shares were acquired for approximately USD $1,415,913,326, funded from the Cevian funds’ general working capital and purchased in British pounds using a conversion rate of USD $1.34725 per GBP 1.00. Cevian reports sole voting and sole dispositive power over all of these shares.
Smith & Nephew plc reported routine share acquisitions by senior management under its Dividend Re-Investment Plan. Following the 2025 final dividend paid on 27 May 2026, the plan automatically purchased ordinary shares of USD 0.20 each on the London Stock Exchange for participating insiders.
Chief Executive Officer Deepak Nath acquired 6,259.14583 ordinary shares at a price of 11.38002 per share, while Chief Financial Officer John Rogers acquired 61.89914 shares at the same price. Other participants included President, Global Operations Paul Connolly, Chief Compliance Officer Alison Parkes, and President, Sports Medicine Scott Schaffner, each completing a single transaction through the plan.